MILAN, Apr. 20 (Class Editori) - Giglio Group will focus also on the healthcare sector. The e-commerce company listed at STAR has signed a framework agreement of indefinite duration with Sinopharm, the pharmaceutical giant listed at the Hong Kong Stock Exchange and established from the joint venture between China National Pharmaceutical Group and the behemoth Fosun. According to a note, it would be a strategic partnership, with the aim of collaborating to the imports of personal protective equipment, such as surgical masks, FFP2 and FFP3, hand sanitizers, gloves, coveralls and protective glasses as well as to the distribution of innovative kits for the detection tests of COVID-19 antibodies.
“The elasticity and flexibility of our logistics structure and our innovative digital platform – apart from allowing a quick widening of the product offer – will allow us to vigorously face the current scenario and optimistically look at our future, already starting from the first semester 2020”, as Alessandro Giglio, CEO and chairman of the namesake group, has explained. “Our company is specialized in the e-commerce design, creation and management at an international level; for this reason, we have always established partnerships with the most important luxury, fashion, food and design brands worldwide: from now on, even with those of the healthcare sector. The Food and Design e-commerce sector is significantly growing and we have already started recording strong signs of recovery in the fashion field in the Asian continent. Now, the healthcare becomes a fourth line of product in our global digital offer with strong expectations in terms of quick growth”.
The B2B and B2C healthcare platform by Giglio Group will continue its activity in the future, regardless the ongoing health emergency, by providing a wide range of items addressed to personal care, which will be subject to an ever-increasing demand. The agreement with Sinopharm provides also for the import in China of items and healthcare equipment produced by the Italian businesses, thereby contributing to their widespread delivery in the Asian market.
According to a note, Sinopharm is the main Chinese state-owned company in the healthcare sector with research and development, production, logistics and pharmaceutical chains activities. It is the sixth producer worldwide of vaccines and provides more than 80% of the vaccines used in China.
Giglio Group is launching its own B2C website at www.gigliosalute.it. In addition, private individuals, professionals, artisans and small-sized enterprises may buy personal protective equipment (PPE).
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.